{"id":"https://openalex.org/W2416807100","doi":null,"title":"Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs.","display_name":"Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs.","alternate_titles":[],"publication_year":1985,"publication_date":"1985-06-01","ids":{"openalex":"https://openalex.org/W2416807100","mag":"2416807100","pmid":"https://pubmed.ncbi.nlm.nih.gov/4016770"},"language":"en","primary_location":{"id":"pmid:4016770","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/4016770","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer treatment reports","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W2416807100"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001063598","display_name":"David H. Kessel","orcid":"https://orcid.org/0000-0002-3221-9299","observed_orcids":["https://orcid.org/0000-0002-3221-9299"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D Kessel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5055150123","display_name":"Cynthia Wilberding","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C Wilberding","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.3875,"has_fulltext":false,"cited_by_count":44,"citation_normalized_percentile":{"value":0.88627968,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"69","issue":"6","first_page":"673","last_page":"676"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daunorubicin","display_name":"daunorubicin","score":0.953000009059906},{"id":"https://openalex.org/keywords/tiapamil","display_name":"tiapamil","score":0.9240000247955322},{"id":"https://openalex.org/keywords/calcium-channel-blockers","display_name":"calcium channel blockers","score":0.8429999947547913},{"id":"https://openalex.org/keywords/anthracycline-resistance","display_name":"anthracycline resistance","score":0.921999990940094},{"id":"https://openalex.org/keywords/p388-leukemia-cells","display_name":"P388 leukemia cells","score":0.8009999990463257},{"id":"https://openalex.org/keywords/drug-efflux","display_name":"drug efflux","score":0.5149999856948853},{"id":"https://openalex.org/keywords/verapamil","display_name":"verapamil","score":0.8069999814033508},{"id":"https://openalex.org/keywords/nifedipine","display_name":"nifedipine","score":0.9819999933242798},{"id":"https://openalex.org/keywords/drug-accumulation","display_name":"drug accumulation","score":0.5889999866485596},{"id":"https://openalex.org/keywords/anticancer-drug-toxicity","display_name":"anticancer drug toxicity","score":0.5239999890327454}],"concepts":[{"id":"https://openalex.org/C2781021840","wikidata":"https://www.wikidata.org/wiki/Q411659","display_name":"Daunorubicin","level":3,"score":0.9381119012832642},{"id":"https://openalex.org/C2777022698","wikidata":"https://www.wikidata.org/wiki/Q410291","display_name":"Verapamil","level":3,"score":0.9266304969787598},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.8583458662033081},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7841581702232361},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6846588850021362},{"id":"https://openalex.org/C519063684","wikidata":"https://www.wikidata.org/wiki/Q706","display_name":"Calcium","level":2,"score":0.5539923906326294},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5188023447990417},{"id":"https://openalex.org/C2779066535","wikidata":"https://www.wikidata.org/wiki/Q39111","display_name":"Nifedipine","level":3,"score":0.46998751163482666},{"id":"https://openalex.org/C2780847677","wikidata":"https://www.wikidata.org/wiki/Q4674302","display_name":"Aclarubicin","level":4,"score":0.4671439826488495},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.45775023102760315},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3647928237915039},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.31243783235549927},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11209887266159058},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.0},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002621","descriptor_name":"Chemistry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003630","descriptor_name":"Daunorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003630","descriptor_name":"Daunorubicin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004351","descriptor_name":"Drug Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007941","descriptor_name":"Leukemia P388","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011437","descriptor_name":"Propylamines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013976","descriptor_name":"Tiapamil Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055598","descriptor_name":"Chemical Phenomena","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:4016770","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/4016770","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer treatment reports","raw_type":"Journal Article"},{"id":"mag:2416807100","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/4016770","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1483854239","https://openalex.org/W2003813397","https://openalex.org/W1996966081","https://openalex.org/W2059118219","https://openalex.org/W2070990214","https://openalex.org/W1985811545","https://openalex.org/W2001402350","https://openalex.org/W2150262631","https://openalex.org/W2001428267","https://openalex.org/W2161293633"],"abstract_inverted_index":{"Studies":[0],"were":[1],"performed":[2],"with":[3,12,32],"the":[4,21,25,95,102],"anthracycline-responsive":[5],"P388":[6],"murine":[7],"leukemia":[8],"cell":[9,23,104],"line,":[10,24],"and":[11,48,75],"P388/ADR,":[13],"a":[14,57,62],"subline":[15],"selected":[16],"for":[17],"doxorubicin":[18],"resistance.":[19],"In":[20],"P388/ADR":[22,78,103],"observed":[26],"100-fold":[27],"daunorubicin":[28,98],"resistance":[29,99],"is":[30,65],"associated":[31],"an":[33],"outward":[34],"drug":[35],"transport":[36],"system":[37],"which":[38,64],"can":[39],"be":[40],"inhibited":[41],"by":[42],"several":[43],"calcium":[44,86],"antagonists,":[45],"eg,":[46],"verapamil":[47,58,70],"nifedipine.":[49],"An":[50],"examination":[51],"of":[52,84,97],"compounds":[53],"related":[54],"to":[55,92],"tiapamil,":[56],"analog,":[59],"has":[60],"identified":[61],"structure":[63],"tenfold":[66],"more":[67],"effective":[68],"than":[69],"at":[71],"potentiating":[72],"anthracycline":[73],"accumulation":[74],"responsiveness":[76],"in":[77,101],"cells.":[79],"At":[80],"no":[81],"nontoxic":[82],"level":[83],"any":[85],"antagonist":[87],"examined":[88],"was":[89],"it":[90],"possible":[91],"wholly":[93],"reverse":[94],"degree":[96],"found":[100],"line.":[105]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2416807100","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
